Table 3.
Sensitivity analyses of the risk ratio of type 1 diabetes
| Analyses | Incidence rate ratios | 95% confidence intervals | P‐value | |
|---|---|---|---|---|
| Analysis 1: setting multiple risk periods (n = 10,400) | ||||
| Before influenza infection (within 180 days) [n = 2,196] | 1.05 | 0.90 | 1.22 | 0.515 |
| After influenza infection (000–180 days) [n = 2,196] | 1.30 | 1.16 | 1.46 | <0.001 |
| After influenza infection (181–360 days) [n = 2,196] | 1.05 | 0.92 | 1.20 | 0.484 |
| Other periods | Reference | ‐ | ‐ | ‐ |
| Analysis 2: by anti‐influenza drug (n = 10,400) | ||||
| All [n = 2,196: Table 2] | 1.30 | 1.15 | 1.46 | <0.001 |
| Oseltamivir [n = 904] | 1.44 | 1.20 | 1.73 | 0.000 |
| Laninamivir [n = 1,151] | 1.26 | 1.07 | 1.48 | 0.006 |
| Zanamivir [n = 499] | 1.39 | 1.05 | 1.82 | 0.020 |
| Peramivir [n = 120] | 1.30 | 0.81 | 2.08 | 0.280 |
| Analysis 3: Changing risk periods from 180 days (n = 10,400) | ||||
| 30 days [n = 2,196] | 0.90 | 0.58 | 1.42 | 0.660 |
| 60 days [n = 2,196] | 1.13 | 0.89 | 1.45 | 0.308 |
| 90 days [n = 2,196] | 1.19 | 1.01 | 1.41 | 0.037 |
| 180 days [n = 2,196: Table 2] | 1.30 | 1.15 | 1.46 | <0.001 |
| 360 days [n = 2,196] | 1.15 | 1.05 | 1.27 | 0.003 |
| Analysis 4: by age group (years) (n = 10,400) | ||||
| 00–19 [n = 985] | 1.44 | 1.21 | 1.71 | <0.001 |
| 20–39 [n = 421] | 1.31 | 1.00 | 1.72 | 0.049 |
| 40–59 [n = 544] | 1.05 | 0.82 | 1.35 | 0.695 |
| 60–79 [n = 220] | 1.50 | 1.03 | 2.16 | 0.033 |
| ≥80 [n = 26] | 0.38 | 0.08 | 1.80 | 0.226 |
| Analysis 5: Changing exposure, from influenza medication to others (ICD‐10 classification codes) (n = 10,400) | ||||
| I (A00–B99; [n = 7,014]) | 1.03 | 0.98 | 1.09 | 0.177 |
| II (C00–D48; [n = 6,029]) | 1.11 | 1.05 | 1.17 | <0.001 |
| III (D50–D89; [n = 3,674]) | 1.04 | 0.97 | 1.12 | 0.274 |
| V (F00–F99; [n = 1,752]) | 1.01 | 0.91 | 1.13 | 0.800 |
| VI (G00–G99; [n = 4,001]) | 1.06 | 0.99 | 1.14 | 0.091 |
| VII (H00–H59; [n = 8,706]) | 1.01 | 0.97 | 1.05 | 0.683 |
| VIII (H60–H95; [n = 2,290]) | 0.99 | 0.90 | 1.09 | 0.885 |
| IX (I00–I99; [n = 6,406]) | 1.09 | 1.03 | 1.15 | 0.003 |
| X (J00–J99; [n = 8,784]) | 1.04 | 0.99 | 1.09 | 0.085 |
| XI (K00–K93; [n = 8,327]) | 1.06 | 1.01 | 1.11 | 0.020 |
| XII (L00–L99; [n = 6,239]) | 1.06 | 1.00 | 1.12 | 0.038 |
| XIII (M00–M99; [n = 5,806]) | 1.04 | 0.98 | 1.10 | 0.160 |
| XIV (N00–N99; [n = 7,682]) | 1.07 | 1.01 | 1.12 | 0.012 |
| XV (O00–O99; [n = 427]) | 1.10 | 0.88 | 1.38 | 0.385 |
| XVI (P00–P96; [n = 65]) | 1.08 | 0.55 | 2.12 | 0.815 |
| XVII (Q00–Q99; [n = 682]) | 1.02 | 0.85 | 1.22 | 0.865 |
| XVIII (R00–R99; [n = 7,029]) | 1.08 | 1.02 | 1.13 | 0.006 |
| XIX (S00–T98; [n = 4,101]) | 1.04 | 0.97 | 1.13 | 0.271 |
| XX (V01–Y98; [n = 160]) | 0.99 | 0.67 | 1.47 | 0.975 |
| XXI (Z00–Z99; [n = 985]) | 1.08 | 0.93 | 1.26 | 0.326 |
| XXII (U00–U89; [n = 130]) | 1.10 | 0.70 | 1.74 | 0.673 |
(The number of all cases analyzed).
[The number of patients experienced both exposures and outcome].